Early cancer diagnostic specialist, Zilico Ltd, has secured further investment from existing investor, Deepbridge Capital and appointed Martin Frost CBE as its new Chairman.Frost joins Zilico as Non-Executive Chair of the Board after stepping down as CEO of CMR Surgical, a surgical robotics company he co-founded and led to successful commercial launch in the UK, mainland Europe and India. In order to launch and scale CMR Surgical, Cambridge’s most recent unicorn, Martin, as CEO, raised more than GBP200 million, a record for a European private medical device company.
Zilico Chief Executive, Sameer Kothari, says: “I am delighted and look forward to working with Martin. We both share the passion for growing businesses which make a difference in people’s lives. These are exciting times as we forge our plans for Zilico.”
Frost succeeds Andrew Newell as Chair.
“On behalf of the Board and all my colleagues, I would like to express my thanks to Andrew for his leadership, commitment and hard work over the last 12 years. My gratitude also extends to Dr Alan Folwell, Jerry Mobbs and Dr Tony Miao for their valuable contributions to the company as they step down from the board.”
Frost says: “I’m really looking forwards to working with Sameer, the Zilico team and investors to help drive important and needed change in the cervical cancer and other clinical areas.”
The new board structure for Zilico sees Dr Savvas Neophytou, a partner of life science investment company, Deepbridge Capital LLP and founding shareholder of a number of technology companies including Torafugu Tech and Cerneretec, continue in his non-executive role at Zilico.
Zilico has developed its proprietary platform technology, Electrical Impedance Spectroscopy (EIS), for cancer diagnosis and is expanding its product development from cervical cancer diagnostics into other, additional clinical areas.
